Gross profit was USD 10.84 million, aMarginof about 58.8% (calculated), compared with USD 10.08 million, or about 58.4%. Management described the margin as just under 59%. Total operating expenses rose to USD 15.2 million from USD 13.2 million, including more than USD 600,000 of …
Key HighlightsCollaboration and licenseRevenuefor the third quarter of 2026 was USD 10.0 million, down from USD 19.1 million a year earlier, because less revenue was recognized under the AbbVie and Gilead agreements.The net loss narrowed to USD 5.9 million, or USD 0.30 per share, …
Key HighlightsAdjusted EBITDA loss was USD 26.3 million in the third quarter of 2026, against USD 21.3 million in the second quarter and USD 15.4 million a year earlier, driven mainly by higherResearch and Developmentspending.Net loss was USD 32.2 million compared with USD 42.1 …
Key HighlightsArbutus Biopharma (NASDAQ:ABUS) reported third-quarterNet Incomeof USD 59.1 million onRevenueof only USD 0.3 million, after a USD 67.3 millionDividendfrom Genevant.ABVC BioPharma (NASDAQ:ABVC) cut its third-quarter net loss 33% to USD 1.39 million with zero revenue, while its filing states substantial doubt about continuing …
Key HighlightsAtossa Therapeutics (NASDAQ:ATOS) held USD 20.6 million of cash at September 30, 2026, and its filing says existing resources are likely insufficient for the next 12 months.Atara Biotherapeutics (NASDAQ:ATRA) reported USD 9.9 million of cash and short-term investments and a March 31, 2027 …
Key HighlightsBiomea Fusion (NASDAQ:BMEA) cut its third-quarter net loss to USD 6.2 million from USD 16.4 million, with USD 26.8 million of cash funding operations only into the second quarter of 2027.Boundless Bio (NASDAQ:BOLD) expects a specialCash Dividendof about USD 44 million to USD …
Key HighlightsCapricor Therapeutics (NASDAQ:CAPR) faces a November 22, 2026 FDA target date for deramiocel after an advisory committee voted 3 in favor and 9 against on cardiomyopathy evidence in July.Cullinan Therapeutics (NASDAQ:CGEM) initiated a New Drug Application for zipalertinib in October 2026 and held …
Key HighlightsHemab Therapeutics (NASDAQ:COAG) held USD 430.2 million of cash, cash equivalents and marketable securities at September 30, 2026, which management said funds operations into 2029.Coya Therapeutics (NASDAQ:COYA) held USD 35.8 million of cash, and its filing states substantial doubt about continuing as a …
Key HighlightsGain Therapeutics (NASDAQ:GANX) reported a USD 3.2 million third quarter net loss and USD 11.7 million of cash, and management flagged substantial doubt about continuing as a going concern.Gossamer Bio (NASDAQ:GOSS) booked a USD 96.2 million loss on issuing warrants, which left other …
Key HighlightsInovio Pharmaceuticals (NASDAQ:INO) reported a USD 49.2 million net loss, of which USD 26.9 million was a non-cashWarrantLiabilitychange, while loss from operations narrowed to USD 19.5 million.SeaStar Medical (NASDAQ:ICU) said netRevenuewas about USD 635,000, up 247%, with cash of about USD 4 million …